Generic Name: pertuzumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Genentech

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Perjeta is a HER2 inhibitor approved for neoadjuvant (pre-surgery) or adjuvant (post-surgery) treatment of early breast cancer, in combination with Herceptin (trastuzumab) and chemotherapy. This combination is also approved for previously untreated metastatic breast cancer.

General Info

About 20% of breast cancers have a high level of human epidermal growth factor receptor 2 (HER2). HER2 plays a role in cell division and repair. Perjeta is a monoclonal antibody that blocks these receptors and slows cancer growth. It was approved in 2012.


Dosing Info: Perjeta is administered as an intravenous infusion, usually every three weeks.

Side Effects

Common side effects of Perjeta combination therapy include diarrhea, hair loss, nausea, fatigue, skin rash and peripheral neuropathy. The combination chills, can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential serious side effects may include heart problems, infusion reactions and severe allergic reactions. Perjeta should not be used during pregnancy.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: December 13, 2018